Crown Laboratories Announces Addition of Thomas Hitchcock, Ph.D. to the Leadership Team

Share Article

Thomas Hitchcock, Ph.D. Joins Crown Laboratories as Chief Science Officer

Crown Laboratories, Inc. (“Crown Laboratories”), a leading, fully integrated skin care company and Hildred Capital Partners LLC (“Hildred”) portfolio company, today announced the appointment of Thomas Hitchcock, Ph.D. as Chief Science Officer. Dr. Hitchcock will oversee Medical Affairs, R&D and Clinical Development for all Crown brands and will hold a Leadership Team position.

Dr. Hitchcock is the Founder of Xycrobe Therapeutics Inc. (http://www.xycrobe.com) and has served as its Chief Executive Officer. Additionally, Dr. Hitchcock served as the Acting Chief Scientific Officer and Vice President of Clinical & Medical Affairs at Bellus Medical from its inception in 2013 up to the acquisition by Crown Laboratories last month. He has more than 20 years of research experience including Basic Science, Proof-of-Concept, Pre-Clinical and Clinical Research across several therapeutic areas such as Cardiology, Oncology, Gene Therapy, Plastic/Facial plastic surgery, Dermatology and Aesthetic medicine.

Jeff Bedard, President and CEO of Crown Laboratories said, “I am delighted to welcome Dr. Hitchcock to Crown. Dr. Hitchcock will be working diligently to move our growing pipeline through the approval and commercialization process. Under Dr. Hitchcock’s leadership and guidance, we look forward to building a strong network of academia to guide us along the path of achieving successful commercialization of current and future products.”

“I’m thrilled to be joining Crown during this time of accelerated growth.” says Dr. Hitchcock. “Given the company’s diverse portfolio and pipeline, my background and expertise align nicely with the organization’s path forward and I am excited at the opportunity to contribute to the innovation across all Crown brands. Innovation, unique technology, and strong leadership will be critical to our success and I am eager to continue to build out the scientific side of the business and help drive the company forward. I have no doubt we have a strong future ahead of us,”

Previous to his work in the industry, Dr. Hitchcock performed research at Weill Cornell Medical College where he studied multiple myeloma genetics. He also performed his Post-doctoral Research in tissue engineering and regenerative medicine at Yale University. During this time, he was first to successfully implant a tissue-engineered human small-diameter artery into a living host. His findings have been presented internationally and printed in a number of noteworthy publications including the Journal of Biological Chemistry, the Annals of the New York Academy of Sciences and a chapter on energy-based devices in Clinics in Plastic Surgery. Dr. Hitchcock earned his Ph.D. in Genetics from Clemson University and completed postdoctoral trainings at Duke University and Yale University in Biomedical Engineering, Vascular Biology and Therapeutics.

About Crown Laboratories, Inc.
Crown Laboratories, Inc. is a privately held, fully integrated global skin care company. Crown Laboratories is committed to developing and providing a diverse portfolio of beauty, consumer, OTC, prescription, medical and aesthetic skin care products that improve the quality of life for its customers. In addition, Crown Laboratories also provides pharmaceutical development and contract manufacturing services for a host of partners world-wide. As an innovative company with key products such as its recently acquired, first FDA-cleared medical grade microneedling device, SkinPen, Blue Lizard Australian Sunscreen, Vita Liberata sunless tanning and skin care, and robust portfolio of Rx and OTC products, Crown Laboratories has enjoyed rapid growth and is poised to become a leader in Dermatology. Crown Laboratories has been listed on the Inc. 5000 Fastest Growing Companies List for six consecutive years. For more information about Crown Laboratories or its products, visit http://www.crownlaboratories.com.

About Hildred Capital Partners
Hildred Capital Partners, LLC is a private investment firm that invests in a broad range of securities, including equity and debt, across geographies and sectors, on both an actively and passively managed basis. Founded in 2014, Hildred has a particular interest in private equity, including situations where the principals can apply their extensive management experience to help a company reach its full potential. Hildred is headed by Howard Solomon, former CEO of Forest Laboratories, and David Solomon, former Senior Vice President, Corporate Development & Strategic Planning at Forest Laboratories, together with Andrew Goldman, the firm’s Chief Investment Officer.

Forward Looking Statements
In this press release, the use of words such as "expect," "anticipate," "possible," "potential," "believe," "commit," "intend," "continue," "may," "would," "could," "should," or similar expressions is intended to identify forward-looking statements that represent Crown Laboratories management’s current judgment about possible future events. We believe these judgments are reasonable, but these statements are not guarantees of any events or results, and actual results may differ materially due to a variety of important factors. Such risks and uncertainties may include, but are not limited to: the satisfaction of closing conditions to the investment by Hildred; the possibility that the transaction will not be completed or, if completed, not completed in the expected timeframe; the potential that the expected benefits and opportunities of the transaction may not be realized or may take longer to realize than expected; and adverse litigation or government action. Crown Laboratories undertakes no obligation to update the information contained in this release.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Jill McGonigle

Hugh Burns/Molly Curry
Hildred Capital Partners
212-433-4600
@BellusMedical
since: 09/2013
Follow >
SkinPen
Like >
Follow us on
Visit website